Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 38,442	$ 32,154
General and administrative	13,000	9,544
Total operating expenses	51,442	41,698
Loss from operations	(51,442)	(41,698)
Total other income, (net):
Interest income	233	483
Other expense	(175)	(145)
Total other income, (net)	58	338
Net loss	(51,384)	(41,360)
Accretion of Series B convertible preferred stock	(7,900)	(7,858)
Net loss attributable to common stockholders—basic and diluted	$ (51,384)	$ (49,218)
Net loss per share applicable to common stockholders—basic and diluted	$ (2.37)	$ (3.53)
Weighted-average common shares outstanding—basic and diluted	21,661,450	13,924,730
Comprehensive loss:
Net loss	$ (51,384)	$ (41,360)
Other comprehensive loss:
Unrealized loss on investments	(20)	(28)
Comprehensive loss	$ (51,404)	$ (41,388)